Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Staphylococcal Infections 1Sepsis 1Infections 1Bacteremia 1

Interventions

Voriconazole 2Daptomycin 2threonic acid 1telavancin 1telaprevir 1soybean oil, phospholipid emulsion 1plerixafor 1peginterferon alfa-2a 1human papillomavirus vaccine, L1 type 16, 18 1fludarabine phosphate 1Whole-Body Irradiation 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Tacrolimus 1Sulfamethoxazole 1Sirolimus 1Rituximab 1Ribavirin 1Peripheral Blood Stem Cell Transplantation 1Ofloxacin 1Methotrexate 1Melphalan 1Magnesium Sulfate 1Human Papillomavirus Recombinant Vaccine nonavalent 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Fluconazole 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Infections × telavancin × Clear all
NCT01321879 2019-12-27

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

M.D. Anderson Cancer Center

Phase 2 Completed
40 enrolled 6 charts

Infections, Staphylococcal Infections, Bacteremia, Sepsis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡